Iovance Biotherapeutics
IOVA
242 hedge funds and large institutions have $1.48B invested in Iovance Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 81 increasing their positions, 87 reducing their positions, and 26 closing their positions.
504% more call options, than puts
Call options by funds: $19.6M | Put options by funds: $3.25M
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
2% more funds holding
Funds holding: 237 → 242 (+5)
7% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 87
3.64% less ownership
Funds ownership: 101.39% → 97.74% (-3.6%)
15% less capital invested
Capital invested by funds: $1.75B → $1.48B (-$269M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
| 3 |
Two Sigma Investments
New York
|
+$10.1M |
| 4 |
Renaissance Technologies
New York
|
+$9.33M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$35.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$24.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$21.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$18.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$17.8M |
IOVA Hedge Fund Activity: Q3 2022 in Review
242 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2022, worth a combined $1.48B — down 15% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new IOVA positions and 26 closed out — a net gain of 6 holders — while 81 added to existing stakes and 87 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $35.1M sold.
- 242 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2022, up from 237 in Q2 2022.
- Funds reported $1.48B of Iovance Biotherapeutics stock for Q3 2022, down 15% quarter-over-quarter.
- 32 funds opened new Iovance Biotherapeutics positions in Q3 2022 and 26 closed out, a net change of +6 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2022 was Goldman Sachs, an estimated $12M added.
- The largest Iovance Biotherapeutics seller in Q3 2022 was Farallon Capital Management, an estimated $35.1M sold.
Based on aggregated 13F filings for Q3 2022.